Navigation Links
Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics

Novel technology opens the door to the understanding of and possible

treatments for obesity, diabetes, ageing and cancer

BILLERICA, Mass., Oct. 6 /PRNewswire/ -- Seahorse Bioscience today announced the release of the first ever analytical instrument for the kinetic measurement of mitochondrial oxygen consumption and cytoplasmic glycolysis in cells in a 96 well microplate. For the past 75 years tools for measuring cellular bioenergetics have been relatively unchanged since Warburg designed the Warburg Apparatus in 1932 and Leland Clark invented the Clark oxygen electrode in 1959.

"Without oxygen consumption measurements, the study of cellular bioenergetics would be in the dark ages," said David Nicholls, a leading bioenergetic researcher from Lund University, Sweden and the Buck Institute, Novato, CA. "Respiratory measurements allow us to quantify subtle changes in ATP turnover, mitochondrial uncoupling or respiratory chain inhibition that can immediately identify an interaction of a compound with the cell's energy generation pathways. Prior to the Seahorse, such studies were restricted to laborious single oxygen consumption measurements using the Clark electrode, invented in 1959, that required large amounts of material and was unsuitable for attached cells. The Seahorse requires just 2% of the material previously needed and has 100-fold the throughput! The ability to analyze cell (and therefore mitochondrial) respiration in a 96 well format and at the same time measure glycolytic flux will result in an immediate surge of scientific discoveries and new drugs. In particular it can lead to an early warning if a potential drug interacts with the cell's bioenergetic pathways."

Martin Brand, a leading mitochondrial researcher from the Buck Institute, Novato, CA and the MRC Dunn Human Nutrition Unit, Cambridge, UK comments, "I have been performing individual measurements of oxygen consumption and lactate production using cell suspensions for the greater part of my career and I trust Seahorse's XF technology, which allows us to make multiple simultaneous measurements of oxygen consumption and acid production using cells growing on culture plates," he said. "The XF format allows us to analyze the bioenergetics of cells under normal growth conditions with high throughput, greatly expanding our ability to investigate cellular bioenergetics."

"Seahorse provides a physiologically relevant assay for detecting the effect of RNAi knockdown of mitochondrial genes on cellular bioenergetics," added Vamsi Mootha, from the Broad Institute, MIT and Harvard's Massachusetts General Hospital. "This technology may accelerate the discovery of drugs for mitochondrial diseases."

The XF96 extracellular flux analyzer was developed to provide higher throughput analysis for customers desiring to study mitochondrial function and dysfunction, obesity, diabetes, cancer, ageing disorders, cardiac disease and drug toxicity.

"The first published Seahorse data was reported in a 2006 Nature article. We have been impressed with the breadth and number of new discoveries by the early users of our technology. In only two years, since the introduction of the first XF24 instrument, XF technology has become the new standard for measuring oxygen consumption and glycolysis by cells, replacing the 50 year old Clark Electrode," notes Jay Teich, CEO, Seahorse Bioscience. "And we are confident the XF96 will have a greater impact."

The new XF96 measures the two primary metabolic pathways in cells in minutes, using a label-free, non-destructive method. The easy to use instrument takes little lab space, does not disrupt stand cell culture procedures and provides measurement c.v.'s under 5%, approximately four times better than has been achievable using older technologies.

About Seahorse Bioscience, Inc. Seahorse XF instruments have become the new standard in cellular bioenergetic measurements. Over 200 plus scientists worldwide are advancing their research in understanding the role of cellular bioenergetics in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA.

Media Contact: Steve Chomicz

Phone: 978-671-1673

SOURCE Seahorse Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... held in San Francisco, CA ... solutions to the coronary marketplace. During a satellite ... in Stent Design to Minimize Restenosis", a renowned ... currently available Medinol NIRxcell™ CoCr Coronary Stent System ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
(Date:12/1/2015)...  InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company ... cardiovascular conditions via the inhalation route, today announced that ... Australia . InCarda is planning to undertake its ... in the first half of 2016. The company ... Adelaide and Melbourne.  In addition, ...
Breaking Medicine Technology:
(Date:12/1/2015)... D.C. (PRWEB) , ... December 01, 2015 , ... ... updated, comprehensive website detailing the important role that meat and poultry play ... in meat and poultry, a nutrition quiz where visitors can check their “meat ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated Rental Services (“Integrated ... Industries International, LLC (“JII”). , With support from JII, Integrated Rental is poised ... hospitals, surgery centers, clinics, research labs and medical facilities across the United States. ...
(Date:12/1/2015)... ... 01, 2015 , ... Califia Farms , one of the fastest growing ... won top honors in Beverage World Magazine’s Global Packaging Design Awards, taking home the ... been selected as a 2015 U.S.A. Taste Champion in the American Masters of Taste ...
(Date:12/1/2015)... ... December 01, 2015 , ... December ... seen vast improvements in scientific research and discoveries, leading us to better understand ... and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
Breaking Medicine News(10 mins):